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Talk of policy has dominated talk of 
science for those interested in embry-
onic stem cell science. But research is 
continuing, and the advances are 
making clear why embryonic stem 
cells are such an important scientiﬁ  c 
and medical resource.
Fraud in a South Korean laboratory 
shoots down a high-fl  ying scientist and 
nicks the country’s pride. A nasty Con-
gressional battle over loosening federal 
restrictions on embryonic stem cell (ESC) 
research ends with President George W. 
Bush’s fi  rst veto. In California, a protracted 
lawsuit stalls the state’s voter-approved 
program for funding stem cell work, 
prompting Governor Arnold Schwarz-
enegger to offer an emergency loan.
Stem cells have hit the front page 
again and again this year—for the wrong 
reasons, researchers say. The ethical, 
political, and fi   nancial commotion has 
over shadowed  the  fi  eld’s  scientifi  c  pro-
gress, which researchers say is accelerating. 
“The literature is burgeoning—it’s some-
times hard to keep up,” says Ian Duncan 
(University of Wisconsin, Madison, 
WI). Although the United States’ regula-
tory environment and limited involvement 
in ESC research slows progress the world 
over, “I’m very pleased with the pace 
we’re going at,” says Alan Trounson 
(Monash University, Melbourne, Aus-
tralia). He heads the Monash Immunology 
and Stem Cell Laboratory, where 120 
scientists are prodding stem cells to 
specialize into kidney, liver, blood, and 
other cell types.
As reviewed recently by Trounson 
(2006), it was Thomson et al. (1998) who 
fi  rst reported the successful isolation of 
human ESCs from blastocysts. Derivation 
without the need for feeder cells was more 
recent (Klimanskaya et al., 2005), and 
refi   nement of culture conditions has 
continued (Hoffman and Carpenter, 
2005). There are now many markers for 
these human ESCs, and they can be trans-
fected and differentiated into ectodermal 
lineages (e.g., oligodendrocytes for possi-
ble myelination; dopaminergic neurons 
potentially for Parkinsonism; and motor 
neurons for possible spinal cord repair), 
mesodermal lineages (cardiomyocytes 
and hematopoietic derivatives), and, with 
more diffi  culty,  endodermal  lineages 
(pancreatic islet–like cells and hepatocyte-
like cells). Several disease-specifi  c lines 
of human ESCs have been developed, thus 
generating models for diseases such as 
Fanconi anemia-A and cystic fi  brosis.
In other labs, researchers are shak-
ing off the effects of the South Korean 
fi  asco and restarting work on somatic cell 
nuclear transfer (SCNT), or therapeutic 
cloning. The technique, which entails 
fusing an unfertilized egg with a nucleus 
from an adult cell, is promising because it 
would generate cells that are genetically 
identical to the patient’s own and thus 
might escape immune attack. In August, 
researchers from Kyoto University in 
Japan reported identifying four genes that 
can regress an adult mouse fi  broblast to 
a stem cell–like state (Takahashi and 
Yamanaka, 2006), and a group at Advanced 
Cell Technology (Worcester, MA) derived 
ESCs from single blastomeres of 8–10-cell 
stage embryos (Fig. 1; Klimanskaya et al., 
2006). According to Arnold Kriegstein, 
who directs the Institute for Regeneration 
Medicine at the University of California, 
San Francisco, the Japanese results could 
offer a solution to “the ethical dilemma 
that plagues this kind of work”: how to 
obtain embryos for research. Although no 
treatments that rely on ESCs have made it 
to the clinic, next spring Geron Corporation 
of Menlo Park, CA, expects to begin phase 
I trials of a therapy for spinal cord injuries.
To assess the state of the fi  eld, we 
check in with fi  ve bench scientists who 
are pushing embryonic cells to be all that 
they can be. The projects they are tackling 
include a survey of what gives an ESC its 
identity, new attempts at deriving ESCs 
from SCNT, perfecting the transformation 
of ESCs into either oligodendrocytes that 
make myelin or pancreatic cells that make 
insulin, and creating an ESC-based model 
for Alzheimer’s disease.
Proﬁ  le of potential
An ESC has the capacity to transform into 
myriad cell types, but it is unclear what 
gene activities confer that ability. One 
possible factor that intrigues researchers 
such as Jeanne Loring (Burnham Institute 
for Medical Research, La Jolla, CA) is the 
distribution of methyl groups on the cell’s 
DNA. Methyl groups don’t just fl  ip genes 
off; their effect on gene expression is 
complicated, Loring says. But methyla-
tion patterns do seem to shape a cell’s 
developmental decisions. After fertilization, 
for example, eggs shed their methyl 
groups as they prepare to divide and dif-
ferentiate. Although other researchers 
have measured methylation on individual 
ESC genes, nobody has tracked the tags 
across the genome.
Loring and colleagues used micro-
arrays to check for methyl attachments at 
more than 1,500 sites scattered across 371 
genes. The researchers compared the marks 
in 14 ESC lines to those in adult stem cells 
and cancer cells. Previous work on gene 
expression suggests that more genes are 
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active in ESCs than in more specialized 
cells, and Loring expected a similarly 
“wide-open” arrangement when it came 
to methylation. However, 35% of the 
sites bore methyl groups in ESCs, 3% 
more than in adult stem cells (Bibikova 
et al., 2006).
Although ESCs weren’t as free and 
easy as the researchers expected, the 
cells did show a distinct methylation 
signature that separated them from adult 
stem cells, cancer cells, and differenti-
ated cells. That pattern might underlie 
the cell’s versatility, Loring says, and 
might help researchers track down the 
genes that bestow this ability. Loring 
and her colleagues are developing larger 
arrays to assess more genes. She would 
like to test a cell produced through 
SCNT to see whether its methylation 
signature matches that of ESCs.
Mergers and acquisitions
Once is defi  nitely not enough for Alison 
Murdoch (Newcastle Fertility Centre at 
Life and University of Newcastle in the 
UK). Last year, her group used SCNT to 
create a human blastocyst, a feat matched 
by only one other researcher, discredited 
South Korean scientist Woo Suk Hwang. 
The blastocyst perished before yielding 
any stem cells, and Murdoch and col-
leagues see it as only a start. They hope 
to refi  ne the SCNT technique until mint-
ing a cell line that matches a patient’s 
tissues is “reliable and routine,” she 
says. The procedure is illegal in some 
countries that permit other forms of ESC 
work (Fig. 2), and no other lab in the 
UK has government sanction for this 
type of research, Murdoch says. But 
she’ll soon have company. Scientists at 
Harvard, the University of California, 
San Francisco, and at least four other 
institutions plan to pursue SCNT.
Murdoch’s position at the head of 
the pack is ironic because, when her team 
published its results in June of last year 
(Stojkovic, et al., 2005), it looked like an 
also-ran. The month before, Hwang and 
colleagues had announced fantastic suc-
cess with SCNT, claiming not only to 
have created human blastocysts, but to 
have turned them into 11 ESC lines. 
Murdoch and company, meanwhile, 
reported comparatively modest results 
using 36 unfertilized eggs and donor nuclei 
from ESCs. Nuclei from ESCs are pre-
sumably easier to genetically reprogram 
to an uncommitted state. To unite eggs 
and nuclei, the researchers goaded them 
with a combination of chemical and elec-
trical stimulation. Only three of the fused 
cells launched into division, and only one 
went further. Compared with Hwang’s 
abundance of blastocysts and ESCs, the 
results “seemed like a tiny, tiny advance,” 
Murdoch says. By the time Hwang’s scam 
came to light in late 2005—investigators 
determined that his group had produced a 
few human blastocysts but no ESC lines—
Murdoch’s team had diverted to other 
questions. “We thought the technology 
[for SCNT] was there,” she says. “It set us 
back a year at least.”
Now that the lost year is over, the 
group is trying to pin down the problems 
that impede SCNT. Murdoch won’t reveal 
what obstacles they’ve identifi  ed, but one 
limitation has loomed from the start: a 
shortage of eggs. SCNT works best on 
eggs freshly removed from a woman’s 
body. But Murdoch and colleagues found 
that, even if they convinced in vitro fertil-
ization patients to donate spare eggs, they 
could only garner a grand total from all 
the patients of about 10 eggs per month 
(Choudhary, et al., 2006). The Harvard 
team plans to solicit egg donations from 
young, healthy women. However, the UK 
body that regulates ESC research has 
rejected on ethical grounds Murdoch’s 
application to tap the same source. She 
plans to apply again. With good eggs 
scarce, researchers like her who have 
worked with in vitro fertilization have an 
advantage, says Murdoch. They are adept 
at coaxing star performances from a 
single, recalcitrant egg.
Good conduct
Eggs aren’t the only cells vexing research-
ers. Human ESCs follow a different time-
table than do the rodent stem cells that 
scientists are more accustomed to work-
ing with, says Duncan. Like the animals 
themselves, rodent stem cells are frenetic, 
dividing and differentiating swiftly. By 
comparison, human ESCs are leisurely—
and fragile. Moreover, human ESCs shrug 
off the growth factors that galvanize their 
mouse counterparts. Because researchers 
know so little about rearing human ESCs, 
the obstacles holding up progress in the 
fi  eld are more technical than intellectual, 
he says.
For seven years, Duncan and col-
leagues have been trying to prod ESCs 
to mature into oligodendrocytes. In the 
central nervous system, these cells make 
myelin, the fatty material that insulates 
nerves. An infusion of oligodendrocytes 
might help ease the symptoms of multiple 
sclerosis—in which myelin deteriorates 
under immune system assault—and several 
inherited diseases in which the material 
breaks down or doesn’t form.
Duncan and colleagues started by 
growing mouse ESCs into oligodendro-
cytes and transplanting them into the 
spinal cords of rats that lacked myelin. 
The implants settled in and laid down new 
insulation (Brüstle et al., 1999). Next, 
Figure 2.  A world of regulation. Current regulatory status for embryonic stem cells by country.
Figure 1.  Research on embryonic stem cells 
marches on. One of the new methods for gener-
ating ESCs involves using a single blastomere.
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Duncan teamed up with University of 
Wisconsin colleague Su-Chun Zhang and 
other researchers to try a similar experi-
ment with human cells (Zhang et al., 
2001). They nudged human ESCs into 
differentiating into nervous system pre-
cursor cells. In the lab dish, these cells 
would mature into several types of cells, 
including neurons, astrocytes, and a few 
oligodendrocytes. But when the researchers 
inserted the precursors into immuno-
defi  cient mice, no oligodendrocytes de-
veloped, and no new myelin formed. 
Hans Keirstead of the University of Cali-
fornia, Irvine, and colleagues (Nistor 
et al., 2005) have achieved these feats, 
Duncan notes. To improve their cells’ per-
formance, Duncan and colleagues are fo-
cusing on a molecular decision maker, the 
transcription factor Olig2. They plan to 
follow its expression during differentia-
tion to understand how it helps a cell 
choose a particular path.
To 𝗃 or not to 𝗃
The options for patients with type I dia-
betes are sour: continued insulin doses 
or an infusion of pancreatic islets that 
contain hormone-making β cells. Al-
though islet transplants can help control 
blood sugar levels, donors are scarce 
and the benefi  ts often wane after a few 
months or years. Henrik Semb’s lab 
(Lund University, Sweden) is one of 
several around the world hunting for a 
recipe that will drive ESCs to morph 
into β cells, thereby providing an alter-
native source for transplants. Nobody 
has gotten an ESC to go all the way, but 
with a helping paw from mice, Semb 
and colleagues have cultivated human 
cells that manufacture insulin.
Even under normal culture condi-
tions, human ESCs began to differentiate 
and produce a transcription factor, Pdx1, 
that characterizes β cells, Semb’s group 
found. Pdx1’s presence suggests that the 
cells had started along the right road. 
However, they wouldn’t go further and 
crank out insulin. To provide a boost, 
Semb and colleagues packed the cells into 
a section of mouse pancreas and tucked 
them under a rodent’s kidney. The change 
of surroundings did the trick. Not only did 
the cells harbor three transcription fac-
tors—including Pdx1—that mark β cells, 
but they made the raw form of insulin 
(Brolén et al., 2005). “We are fairly confi  -
dent that the cells are really close to a 
β cell,” Semb says. This technique couldn’t 
produce transplant-ready β cells because 
of the danger of contamination with 
mouse proteins, which could trigger an 
attack by the recipient’s immune system. 
To overcome that problem, the researchers 
are working to decipher the signals be-
tween the endoderm, which gives rise to 
β cells, and the surrounding mesenchyme 
in the developing pancreas.
Stem cell stand-ins
Mouse models capture some aspects of 
Alzheimer’s disease (AD), amassing the 
β-amyloid plaques that riddle the brains 
of patients with the fatal illness. But the 
animals share one big drawback, says 
Larry Goldstein (University of California, 
San Diego, CA): “They don’t really get 
AD.” Why the rodents don’t lose their 
memories isn’t certain—their physiology 
might differ in a key way from ours, or 
they might not live long enough to de-
velop symptoms, he says. Searching for a 
more human alternative, Goldstein and 
colleagues turned to models that don’t 
even have brains—ESCs. The cells are an 
improvement over existing neural cultures 
because they live longer and are easier to 
grow, and therefore are easier to geneti-
cally modify, says Goldstein.
For the last 18 months, Goldstein’s 
group has been coaxing the versatile cells 
into specializing into neurons. The re-
searchers are still learning how to keep 
human stem cells happy—Goldstein de-
scribes them as “high-maintenance”—and 
nudge them down the right path. “We’ve 
had to develop a lot of the methodology 
ourselves,” he says.
Goldstein plans to deploy the neurons 
to test an alternative hypothesis for AD’s 
cause. The leading explanation blames 
β-amyloid buildup for starting the dis-
ease. But Goldstein wants to determine 
whether AD begins when the cell’s trans-
portation system goes haywire. In the axon 
of a neuron, a protein called kinesin-I 
trucks vesicles, organelles, and other 
molecular cargo away from the cell body, 
running on microtubules that function like 
railroad tracks. Last year, Goldstein’s 
team reported that they found train wrecks 
of vesicles and organelles in brain neurons 
from an AD mouse model and from pa-
tients in the early stages of the illness 
(Stokin et al., 2005). More pile-ups 
formed in mice that fashioned 50% less 
kinesin than normal. Furthermore, the 
brains of kinesin-poor animals accrued 
more β-amyloid plaques, suggesting that 
the transportation tie-up somehow spurs 
the protein’s accumulation. To evaluate 
that explanation, the researchers are geneti-
cally altering ESCs to cut kinesin levels 
and to carry mutations associated with 
inherited varieties of AD.
Lab-reared neurons won’t supplant 
mouse models, but they’ll be essential for 
probing what instigates AD and for test-
ing possible treatments, Goldstein says. 
“I don’t see how you can generate a molec-
ular description of the pathogenic events if 
you don’t work on human cells,” he says.
Mitch Leslie 
mitchleslie@comcast.net
References
Bibikova, M., E. Chudin, B. Wu, L. Zhou, E. 
Wickham Garcia, Y. Liu, S. Shin, T.W. 
Plaia, J.M. Auerbach, D.E. Arking, et al. 
2006. Human embryonic stem cells have a 
unique epigenetic signature. Genome Res. 
doi:10.1101/gr.5319906.
Brolén, G.K., N. Heins, J. Edsbagge, and H. Semb. 
2005. Signals from the embryonic mouse 
pancreas induce differentiation of human 
embryonic stem cells into insulin-producing 
β-cell-like cells. Diabetes. 54:2867–2874.
Brüstle, O., K.N. Jones, R.D. Learish, K. Karram, K. 
Choudhary, O.D. Wiestler, I.D. Duncan, and 
R.D. McKay. 1999. Embryonic stem cell-de-
rived glial precursors: a source of myelinating 
transplants. Science. 285:754–756.
Choudhary, M., M. Nesbitt, C. Leary, and A.P. 
Murdoch. 2006. Donation of fresh oocytes 
for nuclear transfer research–a new approach. 
Reprod. Biomed. Online. 13:301–302.
Hoffman, L.M., and M.K. Carpenter. 2005. 
Characterization and culture of human 
embryonic stem cells. Nat. Biotechnol. 
23:699–708.
Nistor, G.I., M.O. Totoiu, N. Hague, M.K. Carpenter, 
and H.S. Keirstead. 2005. Human embryonic 
stem cells differentiate into oligodendrocytes 
in high purity and myelinate after spinal cord 
transplantation. Glia. 49:385–396.
Klimanskaya, I., Y. Chung, S. Becker, S.-J. Lu, and 
R. Lanza. 2006. Human embryonic stem 
cell lines derived from human blastomeres. 
Nature. doi:10.1038/nature05142.
Because researchers know 
so little about rearing 
human ESCs, the obstacles 
holding up progress in the 
ﬁ  eld are more technical 
than intellectual.JCB • VOLUME 174 • NUMBER 6 • 2006  746
Klimanskaya, I., Y. Chung, L. Meisner, J. Johnson, 
M.D. West, and R. Lanza. 2005. Human em-
bryonic stem cells derived without feeder 
cells. Lancet. 365:1636–1641.
Stojkovic, M., P. Stojkovic, C. Leary, V.J. Hall, L. 
Armstrong, M. Herbert, M. Nesbitt, M. Lako, 
and A. Murdoch. 2005. Derivation of a human 
blastocyst after heterologous nuclear transfer 
to donated oocytes. Reprod. Biomed. Online. 
11:226–231.
Stokin, G.B., C. Lillo, T.L. Falzone, R.G. Brusch, E. 
Rockenstein, S.L. Mount, R. Raman, P. Davies, 
E. Masliah, D.S. Williams, and L.S. Goldstein. 
2005. Axonopathy and transport defi  cits early 
in the pathogenesis of Alzheimer’s disease. 
Science. 307:1282–1288.
Takahashi, K., and S. Yamanaka. 2006. Induction of 
pluripotent stem cells from mouse embryonic 
and adult fi  broblast cultures by defi  ned fac-
tors. Cell. 126:663–676.
Thomson, J.A., J. Itskovitz-Eldor, S.S. Shapiro, M.A. 
Waknitz, J.J. Swiergiel, V.S. Marshall, and 
J.M. Jones. 1998. Embryonic stem cell lines 
derived from human blastocysts. Science. 
282:1145–1147.
Trounson, A. 2006. The production and directed dif-
ferentiation of human embryonic stem cells. 
Endocr. Rev. 27:208–219.
Zhang, S.C., M. Wernig, I.D. Duncan, O. Brüstle, 
and J.A. Thomson. 2001. In vitro differentia-
tion of transplantable neural precursors from 
human embryonic stem cells. Nat. Biotechnol. 
19:1129–1133.